Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2003 1
2004 1
2005 1
2009 1
2016 1
2018 2
2020 1
2021 6
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Serum neurofilament light-chain levels and long-term treatment outcomes in relapsing-remitting multiple sclerosis patients: A post hoc analysis of the randomized CombiRx trial.
Cutter G, Rudick RA, de Moor C, Singh CM, Fisher E, Koster T, Lublin FD, Wolinsky JS, McFarland H, Jacobson S, Naylor ML. Cutter G, et al. Among authors: naylor ml. Mult Scler J Exp Transl Clin. 2023 Apr 27;9(2):20552173231169463. doi: 10.1177/20552173231169463. eCollection 2023 Apr-Jun. Mult Scler J Exp Transl Clin. 2023. PMID: 37139460 Free PMC article.
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Reder AT, Centonze D, Naylor ML, Nagpal A, Rajbhandari R, Altincatal A, Kim M, Berdofe A, Radhakrishnan M, Jung E, Sandrock AW, Smirnakis K, Popescu C, de Moor C. Reder AT, et al. Among authors: naylor ml. CNS Drugs. 2021 Mar;35(3):317-330. doi: 10.1007/s40263-021-00804-1. Epub 2021 Mar 20. CNS Drugs. 2021. PMID: 33743151 Free PMC article.
Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.
Cohen JA, Bermel RA, Grossman CI, Hersh CM, Hyland M, Mowry EM, Naismith R, Naylor ML, Nicholas J, Rajbhandar R, Singh CM, Tintorè M, Zabalza A, Ziemssen T, Williams JR, Montalban X. Cohen JA, et al. Among authors: naylor ml. Mult Scler. 2022 Jun;28(7):1131-1137. doi: 10.1177/13524585211061343. Epub 2022 Jan 7. Mult Scler. 2022. PMID: 34994577 Free PMC article.
Safety and clinical effectiveness of peginterferon beta-1a for relapsing multiple sclerosis in the real-world setting: Interim results from the Plegridy Observational Program.
Salvetti M, Wray S, Nelles G, Altincatal A, Kumar A, Koster T, Naylor ML; Plegridy Observational Program investigators. Salvetti M, et al. Among authors: naylor ml. Mult Scler Relat Disord. 2022 Jan;57:103350. doi: 10.1016/j.msard.2021.103350. Epub 2021 Oct 29. Mult Scler Relat Disord. 2022. PMID: 35158459 Free article.
Early treatment responses to peginterferon beta-1a are associated with longer-term clinical outcomes in patients with relapsing-remitting multiple sclerosis: Subgroup analyses of ADVANCE and ATTAIN.
Newsome SD, Scott TF, Arnold DL, Altincatal A, Naylor ML. Newsome SD, et al. Among authors: naylor ml. Mult Scler Relat Disord. 2022 Jan;57:103367. doi: 10.1016/j.msard.2021.103367. Epub 2021 Nov 3. Mult Scler Relat Disord. 2022. PMID: 35158473 Free article. Clinical Trial.
19 results